aid: sionna-therapeutics
name: Sionna Therapeutics
description: 'Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical
  company headquartered at 21 Hickory Drive, Waltham, Massachusetts, working to revolutionize the
  treatment paradigm for cystic fibrosis (CF) by developing novel small molecules that normalize the
  function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Building on more
  than a decade of its co-founders'' research, the company advances a pipeline of first-in-class
  stabilizers of CFTR''s nucleotide-binding domain 1 (NBD1) — the domain that carries F508del, the most
  common CF-causing mutation — including SION-719 and SION-451, alongside a portfolio of complementary
  CFTR modulators such as SION-2222 (galicaftor) and SION-109 designed to work synergistically with the
  NBD1 stabilizers. Sionna operates purely as a drug-development organization: its public web presence
  is a nine-page WordPress marketing site covering science, pipeline, careers, contact and legal
  material, plus a hosted investor-relations portal. It publishes no developer program, public API,
  SDK, webhook surface, or machine-readable specification of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/sionna-therapeutics/refs/heads/main/apis.yml
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
image: https://www.sionnatx.com/wp-content/uploads/share_news-from-sionna.jpg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-27'
modified: '2026-08-27'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Drug Development
- Rare Disease
- Cystic Fibrosis
- Small Molecule
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Sionna Therapeutics is a clinical-stage biopharmaceutical company whose product is a small-molecule
    CFTR modulator, not software — its entire public surface is a nine-page WordPress marketing site
    (home, about, science, pipeline, careers, contact, legal) whose Yoast sitemap lists no developer,
    API or documentation page, and the only machine-readable endpoint on the host is the default
    WordPress /wp-json/ CMS route table (343 core/plugin routes, no product API).
  evidence:
  - url: https://www.sionnatx.com/openapi.json
    status: 404
  - url: https://www.sionnatx.com/developers
    status: 404
  - url: https://www.sionnatx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.sionnatx.com/.well-known/security.txt
    status: 404
  - url: https://www.sionnatx.com/page-sitemap.xml
    status: 200
  - url: https://api.github.com/orgs/sionna-therapeutics
    status: 404
  - url: https://investors.sionnatx.com/
    status: 0
  checked: '2026-08-27'
common:
- type: DomainSecurity
  url: security/sionna-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/sionna-therapeutics-llms.txt
- type: Website
  url: https://www.sionnatx.com/
- type: About
  url: https://www.sionnatx.com/about-us/
- type: Science
  url: https://www.sionnatx.com/our-science/
- type: Pipeline
  url: https://www.sionnatx.com/pipeline/
- type: Careers
  url: https://www.sionnatx.com/join-us/
- type: Contact
  url: https://www.sionnatx.com/contact-us/
- type: PrivacyPolicy
  url: https://www.sionnatx.com/privacy-policy/
- type: TermsOfService
  url: https://www.sionnatx.com/terms-of-use/
- type: InvestorRelations
  url: https://investors.sionnatx.com/
- type: SecondaryMarket
  url: https://forgeglobal.com/sionna-therapeutics_stock/
x-enrichment:
  date: '2026-08-27'
  status: minimal
  artifacts_added: 3
  pass: local-v1